


WEST Search History

DATE: Monday, March 12, 2007

Hide? Set Name Query**Hit Count***DB=USPT; PLUR=YES; OP=ADJ*☐ L1 (546/234.CCLS. OR 514/331.CCLS.) AND OPIO\$5 73

END OF SEARCH HISTORY

=> d 15
 L5 HAS NO ANSWERS
 L5 STR



VPA 16-2/3/4 U
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 3 10
 NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

=> d his 16

(FILE 'REGISTRY' ENTERED AT 08:52:32 ON 12 MAR 2007)
 L6 3 S L5

=> d his 17

(FILE 'REGISTRY' ENTERED AT 08:52:32 ON 12 MAR 2007)
 L7 255 S L5 FUL

=> d 19
 L9 HAS NO ANSWERS
 L9 STR

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 11 Mar 2007 (20070311/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 110

L11 21 L10

=> s 111 and py<=2003

23916432 PY<=2003

L12 12 L11 AND PY<=2003

=> s 111 not 112

L13 9 L11 NOT L12

=> d bib abs 1-9

L13 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1065561 CAPLUS

DN 145:418953

TI Preparation of N-pyridyl heterocyclyl sulfonamides as 11 β -
hydroxysteroid dehydrogenase type 1 modulators

IN Cheng, Hengmiao; Cripps, Stephen James; Dress, Klaus Ruprecht; Huang,
Buwen; Nair, Sajiv Krisham; Wang, Yong

PA Pfizer Inc., USA

SO PCT Int. Appl., 72pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006106423	A2	20061012	WO 2006-IB941	20060329
	WO 2006106423	A3	20070104		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	NL 1031532	A1	20061010	NL 2006-1031532	20060406
	US 2007027118	A1	20070201	US 2006-398810	20060406
PRAI	US 2005-669613P	P	20050407		
	US 2006-772495P	P	20060210		
OS	MARPAT 145:418953				
GI					



AB The title compds. I [R1 = (un)substituted 2-pyridyl which is optionally fused; b = 2; NR2R3 = (un)substituted 4-11 membered heterocyclyl], useful as 11 β -hydroxysteroid dehydrogenase type 1 modulators, were prepared E.g., a 2-step synthesis of II, starting from 2-amino-4,6-dimethylpyridine, was given. Compds. I were tested in 11 β -hsd-1 assay. For example, II showed 95.9% inhibition at 0.1 μ M. The invention also relates to pharmaceutical compns. comprising the compds. I and methods of treating a condition that is mediated by the modulation of the 11 β -hsd-1 enzyme.

L13 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:494266 CAPLUS

DN 145:8190

TI Preparation of N-[(piperazinylmethyl)biphenyl]benzamide derivatives as M3 muscarinic acetylcholine receptor antagonists

IN Budzik, Brian; Jin, Jian; Laine, Dramane; Mcclelland, Brent; Palovich, Michael; Rivero, Ralph; Wang, Yonghui; Xie, Haibo; Zhu, Chongjie; Cooper, Anthony

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 106 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006055553	A2	20060526	WO 2005-US41346	20051115
	WO 2006055553	A3	20060908		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-627986P	P	20041115		
OS	MARPAT 145:8190				
GI					



II

AB Title compds. I [wherein Ar1, Ar2 = independently (un)substituted Ph or monocyclic heteroaryl; R6 = (un)substituted amine; X = C(R1)p when m = 0-3; X = CO when m = 1; a = 0-2; b = 0-2; c = 0-3; n = 0-3; Y = CO, SO, SO2, HNC(O) or OC(O); Z = (un)substituted (hetero)aryl, alkenyl, alkyl, etc.; R1, R2, R9 = independently H, (un)substituted (cyclo)alkyl, heterocyclyl, etc.; R3 = (un)substituted N+ containing cyclyl; or pharmaceutically acceptable salts thereof] were prepared as M3 muscarinic acetylcholine receptor antagonists. For instance, solid-phase synthesis of II·4CF3CO2H was realized in an overall yield of 52%, via (1) amination of DMHB (2,6-dimethoxy-4-polystyrenebenzyloxybenzaldehyde) resin-bound 3-bromo-4-fluorobenzylamine with 3-formylbenzoic acid; (2) reductive amination with 1-methylpiperazine; (3) Pd-catalyzed coupling with 3-formylphenylboronic acid; (4) reductive amination with (S)-2-methylpiperazine; (5) methylation with MeI; and (6) cleavage from the resin with TFA. Biol. assay for inhibition of receptor activation by calcium mobilization and pharmaceutical formulations were described. I and pharmaceutical compns. are potentially useful for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as respiratory tract disorders.

L13 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:489675 CAPLUS

DN 145:8196

TI Preparation of nitrogen-containing heterocyclic compounds as acetyl-CoA carboxylase inhibitors, their prodrugs, and pharmaceuticals containing them

IN Kamata, Makoto; Koyama, Naoki

PA Takeda Chemical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 68 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006131559	A	20060525	JP 2004-323008	20041105
PRAI	JP 2004-323008		20041105		
OS	MARPAT 145:8196				
GI					



AB The compds. I [E = (un)substituted non-spiro cyclic group; if the cyclic group is monocyclic, then it has ≥ 2 (un)substituted cyclic group; D, G = CO, SO₂; ring P = (un)substituted 5-6-membered nonarom. heterocycle; ring Q = (un)substituted aromatic ring, nonarom. heterocycle containing ≥ 2 heteroatoms; A, L = C, CH, N; J = (un)substituted hydrocarbonyl, (un)substituted hydroxy, (un)substituted heterocyclyl, (un)substituted amino] or their salts, except 4-[1-(9-anthrylcarbonyl)piperidin-4-yl]-2-(morpholin-4-ylcarbonyl)morpholine, are useful for treatment of obesity, diabetes, hypertension, cardiac failure, diabetic cardiomyopathy, metabolic syndrome, sarcopenia, etc. Thus, 4-[1-(9-anthrylcarbonyl)piperidin-4-yl]-N,N-diethylmorpholine-2-carboxamide, prepared from N,N-diethyl-4-(piperidin-4-yl)morpholin-2-carboxamide hydrochloride (preparation given) and anthracene-9-carboxylic acid, inhibited human acetyl-CoA carboxylase 1 (ACC1) and ACC2 with IC₅₀ of 1.7 and 0.2 μ M, resp. Capsules and tablets containing I were also given.

L13 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:103536 CAPLUS

DN 144:192270

TI Preparation of 2-quinazolinamines and related compounds as MCH-1R receptor modulators

IN Receveur, Jean-Marie; Bjurling, Emelie; Christensen, Ann; Hoegberg, Thomas

PA 7TM Pharma A/S, Den.

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006010446	A2	20060202	WO 2005-EP7318	20050705
	WO 2006010446	A3	20060518		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRAI GB 2004-16728 A 20040727

OS MARPAT 144:192270


GI



I



II



III

AB Title compds. I [A = (un)substituted pyridine, metadiazine, imidazol, etc.; B = (un)substituted benzonitrile, benzodioxole, oxindol, etc; R1 = H, halo, OMe; X = HC=, N=; L1 = CH2, CH2CH2; L2 = CH2, CO; R2 = H, alkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, N-alkylation of amine II with 2-chloro-4-(4-chlorophenyl)quinazoline afforded quinazolinamine III. In MCH-1R receptor binding assays, 13-examples of compds. I exhibited IC50 values <0.5 nM.

L13 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:122806 CAPLUS

DN 142:219154

TI Preparation of 4-phenylpiperidine compounds and their use as modulators of opioid receptors

IN Mchardy, Stanton; Liras, Spiros; Guediche, Sara; Coe, Jotham W.

PA Pfizer, Inc., USA

SO U.S. Pat. Appl. Publ., 21 pp.

CODEN: USXXCO

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005032837	A1	20050210	US 2004-823026	20040413
	CA 2522214	A1	20041021	CA 2004-2522214	20040401
	WO 2004089370	A1	20041021	WO 2004-IB1161	20040401
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				

TD, TG

EP 1615643	A1	20060118	EP 2004-725122	20040401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009436	A	20060418	BR 2004-9436	20040401
JP 2006522792	T	20061005	JP 2006-506479	20040401
NL 1025933	A1	20041018	NL 2004-1025933	20040413
NL 1025933	C2	20051123		
PRAI US 2003-462651P	P	20030414		
WO 2004-IB1161	W	20040401		
OS	CASREACT 142:219154; MARPAT 142:219154			
GI				



AB The subject invention relates to 4-phenylpiperidine derivs. (I) [wherein X = H, halogen, cyano; R1, R2 = H, C1-6 alkyl, -(CH2)k-aryl, or (CH2)k-heteroaryl, wherein alkyl, aryl, or heteroaryl is optionally substituted; or CR1R2 together forms an (un)substituted and optionally fused C3-7 cycloalkyl or 4-7 membered carbocyclic or heterocycloalkyl comprising from one to three hetero moieties selected from O, S, -C(=O), and N; R4 = absent or H, (un)saturated C1-4 alkyl, C1-4 alkoxy, hydroxy-C1-4 alkyl, (CH2)n-NH2, (CH2)n-NH(C1-4 alkyl), (CH2)n-N(C1-4 alkyl)2, (CH2)n-NHCO(C1-4 alkyl), (CH2)n-NO2, (CH2)n-CN, (CH2)n-CONH2, (CH2)n-CONH(C1-4 alkyl), (CH2)n-CON(C1-4 alkyl)2, cyano, NO2, (un)substituted OH; R3, R5 = H, each (un)substituted C1-6 alkyl or C3-6 cycloalkyl, C2-4 alkyl-O-C1-4 alkyl, C2-4 alkyl-NH(C1-4 alkyl), C2-4 alkyl-N(C1-4 alkyl)2, C1-4 alkyl-heterocyclic; R6, R7 = C1-C4 alkyl; n = an integer selected from 0-5] and pharmaceutically acceptable salts thereof. These compds. are useful for treating certain disease states, disorders and conditions mediated by an opioid receptor, for example irritable bowel syndrome, drug addiction or dependency, including alc. addiction, depression, anxiety, schizophrenia, anxiety, schizophrenia, and eating disorders. Thus, to a solution of 2-Methoxyethylamine (76.5 μ L, 0.88 mmol) in ClCH2CH2Cl (2 mL) at room temperature was added trimethylaluminum (440 μ L, 0.88 mmol, 2 M in hexanes) dropwise. The reaction mixture was stirred at room temperature for 1 h, followed by adding a solution of 3-[1-[3-(1-Hydroxycyclohexyl)propyl]-trans-3,4-dimethylpiperidin-4-yl]benzoic acid Me ester > (62 mg, 0.16 mmol) in ClCH2CH2Cl (2 mL), and the reaction mixture was heated to reflux for 24 h to give, after workup, trans-3-[1-[3-(1-Hydroxycyclohexyl)propyl]-3,4-dimethylpiperidin-4-yl]-N-(2-methoxyethyl)benzamide.

AN 2005:55210 CAPLUS
 DN 142:155965
 TI A preparation of arylamine-substituted quinazolinones, useful as α 1A and α 1B adrenoceptor antagonists
 IN Connolly, Terrence Joseph; Keitz, Paul Francis; Lee, Eun Kyung; Li, Jim; Lopez-Tapia, Francisco Javier; McGarry, Patrick Finbar; Melville, Chris Richard; Nitzan, Dov; O'Yang, Counde; Padilla, Fernando; Weinhardt, Klaus Kurt
 PA F. Hoffmann-La Roche Ag, Switz.
 SO PCT Int. Appl., 123 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005005395	A2	20050120	WO 2004-EP6973	20040628
	WO 2005005395	A3	20050506		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004255581	A1	20050120	AU 2004-255581	20040628
	CA 2530312	A1	20050120	CA 2004-2530312	20040628
	EP 1644369	A2	20060412	EP 2004-740373	20040628
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004012285	A	20060919	BR 2004-12285	20040628
	CN 1845924	A	20061011	CN 2004-80025034	20040628
	US 2005038016	A1	20050217	US 2004-884768	20040702
PRAI	US 2003-484570P	P	20030702		
	WO 2004-EP6973	W	20040628		
OS	MARPAT 142:155965				
GI					


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of arylamine-substituted quinazolinones of formula I [wherein: R1 and R2 are the same or different alkyl groups; R3 is H, halogen, CN, or OH, etc.; R4 is H, alkyl, aminoalkyl, or hydroxyalkyl, etc.; Y is (un)substituted alk(en)ylene, heterocyclene, or heterocyclalkylene; Z is C(O) or SO2; Ar is (un)substituted (hetero)aryl], useful as α 1A and α 1B adrenoceptor antagonists. For instance, quinazolinone derivative II was prepared via amination of 2-chloro-6,7-dimethoxy-1H-quinazoline-4-one by N-methyl-[3-(pyrrolidin-1-yl)benzyl]amine with a yield of 60%. The prepared compds. were tested in [3H]prazosin binding (α -adrenoceptor) assay and dog in vitro intraurethral and blood pressure assay. For instance, pKi values for III were 8.49 (α 1A), 7.83 (α 1B), and 5.58 (α 1D).

L13 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:857184 CAPLUS

DN 141:332058
 TI Preparation of 4-phenylpiperidine compounds as modulators of opioid receptors
 IN Mchardy, Stanton; Liras, Spiros; Guediche, Sara; Coe, Jotham W.
 PA Pfizer Inc, USA
 SO U.S. Pat. Appl. Publ., 21 pp.
 *CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004204453	A1	20041014	US 2004-762447	20040122
	CA 2522214	A1	20041021	CA 2004-2522214	20040401
	WO 2004089370	A1	20041021	WO 2004-IB1161	20040401
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1615643	A1	20060118	EP 2004-725122	20040401
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004009436	A	20060418	BR 2004-9436	20040401
	JP 2006522792	T	20061005	JP 2006-506479	20040401
	NL 1025933	A1	20041018	NL 2004-1025933	20040413
	NL 1025933	C2	20051123		
PRAI	US 2003-462651P	P	20030414		
	WO 2004-IB1161	W	20040401		
OS	MARPAT 141:332058				
GI					



AB The title compds. I, wherein X is H, halo or cyano; R is $-(CH_2)_nCR_1R_2R_4$; R1 and R2 are H, alkyl/aryl, etc., or R1 and R2 together with the carbon to which they are attached form certain (un)substituted carbo- or heterocycles; R4 is H, OH, alkyl, NH2, cyano, etc.; R3 and R5 are H, (cyclo)alkyl, etc.; R6 and R7 are alkyl; n is 0-5; with some limitations, useful as modulators of opioid receptors, were prepared. Also disclosed are pharmaceutical compns. comprising I or pharmaceutically acceptable salts thereof in combination with pharmaceutically acceptable carriers, excipients or additives, and methods of using them to treat diseases mediated by opioid receptors, such as irritable bowel syndrome, drug addiction or dependency, depression, anxiety, schizophrenia and eating disorders. Compds. I displayed selective activity for μ -, κ - and δ -opioid receptors in opioid receptor binding assays, and had K_i values of about 200 nM or less for the μ -receptor. For instance, triflate II (Y = OTf, Z = Bn) underwent carbonylation with CO in MeOH followed by debenzoylation to give amine II (Y = CO2Me, Z = H). Reductive amination of this compound with 3-(1-hydroxycyclohexyl)propionaldehyde and subsequent condensation with 2-methoxyethylamine yielded III. Compds. I are biol. advantageous in that they are not metabolized by the P 450 isoenzyme CYP2D6 to an extent which could cause significant dosing or pharmacokinetic variations (no data).

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:817865 CAPLUS

DN 141:314351

TI Preparation of 1,2,4-substituted 1,2,3,4-tetrahydro- and 1,2-dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetyl inhibitors for the treatment of atherosclerosis and obesity

IN Chang, George; Didiuk, Mary Theresa; Finneman, Jari Ilmari; Garigipati, Ravi Shanker; Kelley, Ryan Michael; Perry, David Austen; Ruggeri, Roger Benjamin; Bechle, Bruce Michael

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 335 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004085401	A1	20041007	WO 2004-IB836	20040315
	WO 2004085401	A8	20051201		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004224082	A1	20041007	AU 2004-224082	20040315
	CA 2520405	A1	20041007	CA 2004-2520405	20040315
	EP 1622872	A1	20060208	EP 2004-720668	20040315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008897	A	20060418	BR 2004-8897	20040315
	CN 1795177	A	20060628	CN 2004-80014645	20040315
	JP 2006521344	T	20060921	JP 2006-506369	20040315
	US 2004204450	A1	20041014	US 2004-807838	20040323
	NL 1025839	A1	20040930	NL 2004-1025839	20040326
	NL 1025839	C2	20060906		
	NO 2005004989	A	20051216	NO 2005-4989	20051026
	US 2006122224	A1	20060608	US 2005-305874	20051215
PRAI	US 2003-458274P	P	20030328		
	US 2004-536217P	P	20040114		
	WO 2004-IB836	A	20040315		
	US 2004-807838	A1	20040323		
OS	MARPAT 141:314351				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [X = C; J = N or C, wherein when J = C, then the bond between J and X is a single or double bond, if J = N, then the bond between J and X is a single bond; R1 = Y, W-Z or W-Y; Y = (un)substituted, (un)saturated 3-8 membered ring (or bicyclic ring) optionally having 1-4 heteroatoms, or (un)substituted, (un)saturated 1-10 membered straight or branched carbon chain optionally substituted with 1-2 heteroatoms; W = carbonyl, thiocarbonyl, sulfinyl, or sulfonyl; Z = OY, SY, NHY or NY2; R2 = (un)substituted, (un)saturated 1-6 membered alkyl or heteroalkyl chain; R3 = (un)substituted, (un)saturated alkyl or heteroalkyl chain; R4, R5, R6, and R7 independently = H, bond, nitro, etc.; or adjacent combinations of R4, R5, R6, and R7 may optionally be taken together to form (un)substituted, (un)saturated carbocycle or heterocyclic ring], and pharmaceutical compns. containing such compds. are prepared and disclosed as cholesteryl ester transfer protein (cetp) inhibitors. Thus, e.g., II was prepared by reaction of 3,5-bis(trifluoromethyl)benzoyl chloride with 4-diazo-6,7-dimethoxy-2-methyl-3,4-dihydro-2H-quinoline-1-carboxylic acid Et ester (preparation given) in di-Et ether. Methods for bioassaying compds. I are described (no data). The use of I to elevate certain plasma lipid levels, including high d. lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or

high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans is further disclosed.


RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:565223 CAPLUS
DN 141:123625
TI Preparation of substituted 3,5-dihydro-4H-imidazol-4-ones for the treatment of obesity
IN Chen, Yuanwei; O'Connor, Stephen James; Gunn, David; Newcom, Jason; Chen, Jianqing; Yi, Lin; Zhang, Hai-jun; Hunyadi, Laszlo Matyas; Natero, Reina
PA Bayer Pharmaceuticals Corporation, USA
SO PCT Int. Appl., 344 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058727	A1	20040715	WO 2003-US40843	20031219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003299791	A1	20040722	AU 2003-299791	20031219
PRAI	US 2002-435429P	P	20021220		
	WO 2003-US40843	W	20031219		
OS	MARPAT 141:123625				
GI					



I



II



III

AB The title compds. [I; R1, R2 = alkyl, thienyl, (un)substituted pyridyl, Ph; or R1 and R2 together with the carbon atom to which they are attached can form saturated 5-6 membered carbocyclic ring; Y = (CH₂)_n; n = 0-1; R3 = H, alkyl, alkoxy, cycloalkyl, etc.; X = a bond, (un)substituted alkylene; R4 = (un)substituted II, 4-6 membered saturated heterocyclic ring and (un)saturated monocyclic, bicyclic, or spiroannulated heterocyclic ring] which are useful in the treatment of obesity and obesity-related disorders, and as weight-loss and weight-control agents, were prepared and formulated. E.g., a multi-step synthesis of III (starting from 4-(4-trifluoromethylphenyl)piperidine, difluorobenzil and 4-methoxybenzamidine) was given. The invention also provides pharmaceutical compns. comprising the compds. I, and methods of using such compns. for inducing weight loss and treating obesity and obesity-related disorders.

> d bib 1-12

L14 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:928891 CAPLUS
DN 140:156732
TI trans-3,4-Dimethyl-4-(3-carboxamidophenyl)piperidines: A novel class of
μ-selective opioid antagonists
AU Le Bourdonnec, Bertrand; Belanger, Serge; Cassel, Joel A.; Stabley,
Gabriel J.; DeHaven, Robert N.; Dolle, Roland E.
CS Adolor Corporation, Department of Chemistry, Exton, PA, 19341, USA
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(24),
4459-4462
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 140:156732
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:412801 CAPLUS
DN 139:245782
TI Preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating
Alzheimer's disease
IN Varghese, John; Maillard, Michel; Jagodzinska, Barbara; Beck, James P.;
Gailunas, Andrea; Fang, Larry; Sealy, Jennifer; Tenbrink, Ruth; Freskos,
John; Mickelson, John; Samala, Lakshman; Hom, Roy
PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SO PCT Int. Appl., 1243 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040096	A2	20030515	WO 2002-XA36072	20021108 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2003040096	A2	20030515	WO 2002-US36072	20021108 <--
	WO 2003040096	A3	20040506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	ZA 2004003578	A	20051010	ZA 2004-3578	20040511
PRAI	US 2001-337122P	P	20011108		
	US 2001-344086P	P	20011228		
	US 2002-345635P	P	20020103		
	WO 2002-US36072	A	20021108		

OS MARPAT 139:245782

L14 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:376819 CAPLUS

DN 138:385173

TI Preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease

IN Varghese, John; Maillard, Michel; Jagodzinska, Barbara; Beck, James P.; Gailunas, Andrea; Fang, Larry; Sealy, Jennifer; Tenbrink, Ruth; Freskos, John; Mickelson, John; Samala, Lakshman; Hom, Roy

PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company

SO PCT Int. Appl., 1243 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040096	A2	20030515	WO 2002-US36072	20021108 <--
	WO 2003040096	A3	20040506		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2466284	A1	20030515	CA 2002-2466284	20021108 <--
	WO 2003040096	A2	20030515	WO 2002-XA36072	20021108 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004171881	A1	20040902	US 2002-291318	20021108
	US 7176242	B2	20070213		
	EP 1453789	A2	20040908	EP 2002-793909	20021108
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	BR 2002014035	A	20050426	BR 2002-14035	20021108
	JP 2005520791	T	20050714	JP 2003-542142	20021108
	CN 1759095	A	20060412	CN 2002-826786	20021108
	ZA 2004003578	A	20051010	ZA 2004-3578	20040511
	IN 2004KN00627	A	20060224	IN 2004-KN627	20040514
	NO 2004002359	A	20040806	NO 2004-2359	20040607
PRAI	US 2001-337122P	P	20011108		
	US 2001-344086P	P	20011228		
	US 2002-345635P	P	20020103		
	WO 2002-US36072	W	20021108		

OS MARPAT 138:385173

L14 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:754196 CAPLUS

DN 137:257677

TI Methods of treating or preventing Alzheimer's disease using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes

IN Nieman, James A.; Fang, Lawrence; Jagodzinska, Barbara
PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SO PCT Int. Appl., 449 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002076440	A2	20021003	WO 2002-US9100	20020321 <--
	WO 2002076440	A3	20021128		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002306848	A1	20021008	AU 2002-306848	20020321 <--
	US 2006079533	A1	20060413	US 2004-472868	20040202
PRAI	US 2001-278371P	P	20010323		
	US 2001-308729P	P	20010730		
	WO 2002-US9100	W	20020321		
OS	MARPAT 137:257677				

L14 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:865366 CAPLUS

DN 134:29319

TI Preparation of phenylpiperidines useful in pruritus

IN Armer, Richard Edward; Gethin, David Morris; Gibson, Stephen Paul; Tomassini, Ivan

PA Pfizer Inc., USA

SO Jpn. Kokai Tokkyo Koho, 36 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000344746	A	20001212	JP 2000-153269	20000524 <--
	EP 1072592	A2	20010131	EP 2000-304219	20000518 <--
	EP 1072592	A3	20010207		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2309434	A1	20001128	CA 2000-2309434	20000525 <--
	BR 2000002515	A	20010102	BR 2000-2515	20000529 <--
	US 2002099216	A1	20020725	US 2002-108160	20020327 <--
	US 6812236	B2	20041102		
	JP 2004107324	A	20040408	JP 2003-206497	20030807
	US 2005085456	A1	20050421	US 2004-962794	20041012
PRAI	GB 1999-12411	A	19990528		
	US 2000-575951	B1	20000523		
	JP 2000-153269	A3	20000524		
	US 2002-108160	A3	20020327		
OS	MARPAT 134:29319				

L14 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:742083 CAPLUS

DN 133:309908

TI Preparation of piperazinyladamantylmethylbenzamides and related compounds as P2X7 receptor antagonists.

IN Alcaraz, Lilian; Furber, Mark; Mortimore, Michael

PA AstraZeneca AB, Swed.
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061569	A1	20001019	WO 2000-SE663	20000406 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2368829	A1	20001019	CA 2000-2368829	20000406 <--
	BR 2000009651	A	20020108	BR 2000-9651	20000406 <--
	EP 1171432	A1	20020116	EP 2000-919245	20000406 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200102911	T2	20020121	TR 2001-2911	20000406 <--
	HU 200202214	A2	20021028	HU 2002-2214	20000406 <--
	JP 2002541249	T	20021203	JP 2000-610843	20000406 <--
	EE 200100525	A	20021216	EE 2001-525	20000406 <--
	EE 4565	B1	20051215		
	NZ 514477	A	20030429	NZ 2000-514477	20000406 <--
	AU 774526	B2	20040701	AU 2000-39947	20000406
	RU 2254333	C2	20050620	RU 2001-130140	20000406
	US 6492355	B1	20021210	US 2000-555489	20000601 <--
	IN 2001MN01201	A	20050318	IN 2001-MN1201	20011001
	NO 2001004894	A	20011210	NO 2001-4894	20011008 <--
	NO 321405	B1	20060508		
	ZA 2001008265	A	20030108	ZA 2001-8265	20011008 <--
PRAI	SE 1999-1270	A	19990409		
	GB 2000-2330	A	20000201		
	WO 2000-SE663	W	20000406		

OS MARPAT 133:309908

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:742072 CAPLUS

DN 133:309907

TI Preparation of nitrogen-containing heterocyclic compounds and benzamide compounds as hypolipidemics and antiarteriosclerotics

IN Ohkura, Naoto; Hiraiwa, Yukiko; Matsushima, Tetsuya; Sasaki, Kazue; Yamamoto, Takehiro; Shiotani, Masaharu; Suzuki, Shigeki; Nakatani, Yuuko; Kuroda, Chizuko; Nagasawa, Mieko; Katano, Kiyooki

PA Meiji Seika Kaisha, Ltd., Japan

SO PCT Int. Appl., 284 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061556	A1	20001019	WO 2000-JP2329	20000410 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2369103 A1 20001019 CA 2000-2369103 20000410 <--
BR 2000009650 A 20020102 BR 2000-9650 20000410 <--
EP 1180514 A1 20020220 EP 2000-915465 20000410 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

AU 779550 B2 20050127 AU 2000-36759 20000410
US 6777414 B1 20040817 US 2001-958296 20011005
US 2004224959 A1 20041111 US 2004-868006 20040616
US 7030120 B2 20060418

PRAI JP 1999-102559 A 19990409
JP 1999-118490 A 19990426
JP 1999-119043 A 19990427
WO 2000-JP2329 W 20000410
US 2001-958296 A3 20011005

OS MARPAT 133:309907

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:595493 CAPLUS

DN 133:305270

TI Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and
amide bond orientation are important factors in determining the affinity
of compounds for activated or resting platelet receptors

AU Egbertson, M. S.; Bednar, B.; Askew, B. C.; Bednar, R. A.; Brashear, K.;
Breslin, M. J.; Duggan, M. E.; Fisher, T. E.; Halczenko, W.; Hutchinson,
J. H.; Ihle, N.; Prugh, J. D.; Wai, J. S.; Gould, R. J.; Hartman, G. D.

CS Departments of Medicinal Chemistry and Pharmacology, Merck Research
Laboratories, West Point, PA, 19486, USA

SO Bioorganic & Medicinal Chemistry Letters (2000), 10(17),
1943-1948

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:307688 CAPLUS

DN 126:277402

TI New 4-aryl-3-alkoxypiperidines and -azabicyclooctanes for treating heart
and kidney insufficiency

IN Binggeli, Alfred; Breu, Volker; Bur, Daniel; Fischli, Walter; Gueller,
Rolf; Hirth, Georges; Maerki, Hans-Peter; Mueller, Marcel; Oefner,
Christian; Stadler, Heinz; Vieira, Eric; Wilhelm, Maurice; Wostl, Wolfgang

PA F. Hoffmann-La Roche Ag, Switz.

SO PCT Int. Appl., 492 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9709311	A1	19970313	WO 1996-EP3803	19960829 <--
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, TR				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	IN 1996MA01426	A	20050304	IN 1996-MA1426	19960813
	CA 2230931	A1	19970313	CA 1996-2230931	19960829 <--
	AU 9667432	A	19970327	AU 1996-67432	19960829 <--
	AU 708616	B2	19990805		

EP 863875	A1	19980916	EP 1996-927715	19960829 <--
EP 863875	B1	20030604		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1202152	A	19981216	CN 1996-197674	19960829 <--
JP 11500447	T	19990112	JP 1997-510837	19960829 <--
JP 3648251	B2	20050518		
BR 9610385	A	19990706	BR 1996-10385	19960829 <--
HU 9900926	A2	19990928	HU 1999-926	19960829 <--
NZ 315677	A	20000228	NZ 1996-315677	19960829 <--
RU 2167865	C2	20010527	RU 1998-106388	19960829 <--
AT 242213	T	20030615	AT 1996-927715	19960829 <--
IL 123293	A	20030624	IL 1996-123293	19960829 <--
CZ 292327	B6	20030917	CZ 1998-684	19960829 <--
PT 863875	T	20031031	PT 1996-927715	19960829 <--
ES 2201192	T3	20040316	ES 1996-927715	19960829
ZA 9607424	A	19970307	ZA 1996-7424	19960902 <--
TW 474932	B	20020201	TW 1996-85110684	19960902 <--
NO 9800954	A	19980428	NO 1998-954	19980305 <--
NO 310069	B1	20010514		
US 6051712	A	20000418	US 1999-255185	19990222 <--
HK 1016177	A1	20060901	HK 1999-101299	19990330
US 6150526	A	20001121	US 1999-456283	19991207 <--
PRAI CH 1995-2548	A	19950907		
CH 1996-1876	A	19960726		
WO 1996-EP3803	W	19960829		
US 1996-711339	A3	19960906		
US 1999-255185	A1	19990222		
OS	MARPAT 126:277402			

L14 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:130808 CAPLUS
DN 124:176081
TI Preparation of 1,3-thiazolidin-4-one derivatives and analogs as thrombin receptor antagonists
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 07285952	A	19951031	JP 1995-67197	19950327 <--
PRAI	GB 1994-7018	A	19940408		
	GB 1994-17443	A	19940830		
OS	MARPAT 124:176081				

L14 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:753639 CAPLUS
DN 123:132898
TI Use of substituted 1,4-dihydropyridines to reduce intraocular pressure
IN Bron, Jan; Sterk, Geert Jan; Timmerman, Hendrik; Van Der Werf, Jan Fetze
PA Byk Nederland BV, Neth.
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2

DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9513812	A1	19950526	WO 1994-EP3757	19941112 <--
	W: AU, BG, BY, CA, CN, CZ, EE, FI, HU, JP, KR, LT, LV, NO, NZ, PL, RO, RU, SI, SK, UA, US				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 AU 9481427 A 19950606 AU 1994-81427 19941112 <--
 PRAI CH 1993-3427 A 19931117
 WO 1994-EP3757 W 19941112
 OS MARPAT 123:132898

L14 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1992:235451 CAPLUS
 DN 116:235451
 TI Preparation of 4-[(nitroxyalkoxy)phenyl]-1,4-dihydropyridine-3,5-
 dicarboxylates and related compounds as drugs
 IN Sterk, Geert Jan; Van der Werf, Jan Fetze; Timmerman, Hendrik; Bron, Jan
 PA Cedona Pharmaceuticals B. V., Neth.
 SO PCT Int. Appl., 47 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9202503	A1	19920220	WO 1991-EP1442	19910731 <--
	W: AU, CA, CS, DE, FI, HU, JP, KR, NL, NO, PL, SU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	NL 9001752	A	19920302	NL 1990-1752	19900802 <--
	CA 2088251	A1	19920203	CA 1991-2088251	19910731 <--
	AU 9182801	A	19920302	AU 1991-82801	19910731 <--
	AU 655192	B2	19941208		
	EP 541634	A1	19930519	EP 1991-913914	19910731 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05509094	T	19931216	JP 1991-512770	19910731 <--
	ZA 9106058	A	19920624	ZA 1991-6058	19910801 <--
	US 5378718	A	19950103	US 1993-965270	19930122 <--
	NO 9300306	A	19930129	NO 1993-306	19930129 <--
	NO 180084	B	19961104		
	NO 180084	C	19970212		
PRAI	NL 1990-1752	A	19900802		
	WO 1991-EP1442	A	19910731		
OS	MARPAT 116:235451				

AN 2004:857184 CAPLUS
 DN 141:332058
 TI Preparation of 4-phenylpiperidine compounds as modulators of opioid receptors
 IN Mchardy, Stanton; Liras, Spiros; Guediche, Sara; Coe, Jotham W.
 PA Pfizer Inc, USA
 SO U.S. Pat. Appl. Publ., 21 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004204453	A1	20041014	US 2004-762447	20040122
	CA 2522214	A1	20041021	CA 2004-2522214	20040401
	WO 2004089370	A1	20041021	WO 2004-IB1161	20040401
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1615643	A1	20060118	EP 2004-725122	20040401
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004009436	A	20060418	BR 2004-9436	20040401
	JP 2006522792	T	20061005	JP 2006-506479	20040401
	NL 1025933	A1	20041018	NL 2004-1025933	20040413
	NL 1025933	C2	20051123		
PRAI	US 2003-462651P	P	20030414		
	WO 2004-IB1161	W	20040401		
OS	MARPAT 141:332058				
IT	773081-21-3P 773081-23-5P 773081-25-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of phenylpiperidine compds. as modulators of opioid receptors)				
RN	773081-21-3 CAPLUS				
CN	Benzamide, 3-[(3R,4R)-1-[3-(1-hydroxycyclohexyl)propyl]-3,4-dimethyl-4-piperidiny]-N-(2-methoxyethyl)-, rel- (9CI) (CA INDEX NAME)				

Relative stereochemistry.



RN 773081-23-5 CAPLUS
 CN Benzamide, 3-[(3R,4R)-1-[3-(1-hydroxycyclohexyl)propyl]-3,4-dimethyl-4-piperidiny]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 773081-25-7 CAPLUS

CN Benzamide, 3-[(3R,4R)-1-[3-(1-hydroxycyclohexyl)propyl]-3,4-dimethyl-4-piperidinyl]-N-[(tetrahydro-2-furanyl)methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

